Binay calls for nationwide info drive on controversial dengue vaccine

Binay calls for nationwide info drive on controversial dengue vaccine

In a statement, Sanofi said it had recently examined six years of patient data.

"For those not previously infected by dengue virus, however, the analysis found that in the longer term, more cases of severe disease could occur following vaccination upon a subsequent dengue infection", Sanofi said.

People who catch dengue a few times can be at risk of a hemorrhagic version of the disease. In severe cases, dengue can cause breathing problems, hemorrhaging and organ failure. Sanofi Pasteur stressed that the vaccine still protected against dengue fever when it was given to people who had prior dengue infections.

"The DOH will place the dengue vaccination program on hold while review consultations are ongoing with experts and key stakeholders", Duque announced in a press conference on Friday, December 1.

More news: Applebee's to offer $1 Long Island Iced Tea in December

Sanofi will propose that health authorities update the prescribing information to request that health-care professionals assess the likelihood of prior infection in an individual before vaccinating.

Dengvaxia is the first vaccine to gain approval for the dengue virus, which is a mosquito-borne viral disease with no cure.

The company expects to take a 100 million euro (USD 118 million) loss based on the news. The vaccine is now recommended in most dengue- endemic countries for people over age nine.

While the financial hit may not make much of a dent in Sanofi's fourth quarter earnings, the new data is a setback to the drugmaker's hopes for the vaccine, which was the first treatment ever approved for the virus.